Gregory Craven

Gregory Craven joins the FAS as Assistant Professor of Molecular, Cellular, and Developmental Biology. His work combines organic chemistry, chemoproteomics and structural biology to probe and perturb dysregulated signaling pathways, especially in cancer. He earned a first-class degree in chemistry from the University of Oxford and completed his PhD in chemical biology at Imperial College London. He then conducted postdoctoral research at the University of California, San Francisco (UCSF), where he developed lysine-targeted covalent inhibitors and chemoproteomic methods. Notably, his postdoctoral work led to the discovery of the first mutant-selective inhibitor of AKT1(E17K), a common driver of breast cancer. His lab will be part of Yale’s Institute for Biomolecular Design and Discovery, focusing on the design and characterization of new small molecule probes against cancer.